Inclusion Criteria:  History of stage I-III breast cancer and free of disease by clinical examination;Currently receiving aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) treatment; AI-assisted treatment has lasted for more than one month, and there are obvious symptoms of arthralgia ; Voluntarily participate in the clinical trial and sign the informed consent form after informed consent (patients voluntarily accept the treatment and give informed consent); Eastern Cooperative Oncology Group (ECOG) score of physical condition (0-1); Patients with previous local recurrence were eligible, but not patients with distant metastasis; The basic indexes were consistent, and the blood routine and ECG were normal.  Exclusion Criteria:  Patients with needle phobia; Low platelet count (<50000); comorbidity with a bleeding disorder; comorbidity with thyroid dysfunction; pregnancy; haemoglobin levels <10 g/dl and haematocrit <30; anaemia on active pharmacological treatment orreceiving blood transfusion or steroids; Lymphoedematous of limbs; Patients have a history of acupuncture treatment for 6 months; Patients were reluctant to participate in the study; A prior history of inflammation, metabolic disease, or neurotic joints, except for previous treatment with bisphosphonates, steroids, or opioid analgesics.